Literature DB >> 25511870

Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Sarene Koh1, Antonio Bertoletti.   

Abstract

Therapeutic vaccination for the treatment of chronic hepatitis B has thus far been unsatisfactory. In this review, we discuss potential new therapeutic vaccination strategies and other immunotherapeutic approaches that aim to achieve efficient restoration of HBV immunity in chronically infected patients.

Entities:  

Mesh：

Year:  2014        PMID： 25511870     DOI： 10.1007/s00430-014-0377-7

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  87 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

2.  Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells.

Authors:  Elena Sandalova; Diletta Laccabue; Carolina Boni; Tsunamasa Watanabe; Anthony Tan; Ho Zi Zong; Carlo Ferrari; Antonio Bertoletti
Journal:  Gastroenterology       Date:  2012-04-01       Impact factor: 22.682

3.  Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Authors:  Adam J Gehring; Muzlifah Haniffa; Patrick T Kennedy; Zi Zong Ho; Carolina Boni; Amanda Shin; Nasirah Banu; Adeline Chia; Seng Gee Lim; Carlo Ferrari; Florent Ginhoux; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

4.  Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.

Authors:  Anja Dahmen; Sabine Herzog-Hauff; Wulf O Böcher; Peter R Galle; Hanns F Löhr
Journal:  J Med Virol       Date:  2002-04       Impact factor: 2.327

5.  Oscillating CD8(+) T cell effector functions after antigen recognition in the liver.

Authors:  Masanori Isogawa; Yoshihiro Furuichi; Francis V Chisari
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

6.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.

Authors:  Renate G van der Molen; Dave Sprengers; Rekha S Binda; Esther C de Jong; Hubert G M Niesters; Johannes G Kusters; Jaap Kwekkeboom; Harry L A Janssen
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

7.  Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen.

Authors:  A Penna; F V Chisari; A Bertoletti; G Missale; P Fowler; T Giuberti; F Fiaccadori; C Ferrari
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

8.  Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.

Authors:  Jia Liu; Ejuan Zhang; Zhiyong Ma; Weimin Wu; Anna Kosinska; Xiaoyong Zhang; Inga Möller; Pia Seiz; Dieter Glebe; Baoju Wang; Dongliang Yang; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

9.  A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients.

Authors:  Dao-Zhen Xu; Kai Zhao; Li-Min Guo; Lan-Juan Li; Qing Xie; Hong Ren; Ji-Ming Zhang; Min Xu; Hui-Fen Wang; Wen-Xiang Huang; Wen-Xiang Wang; Xue-Fan Bai; Jun-Qi Niu; Pei Liu; Xin-Yue Chen; Xin-Liang Shen; Zheng-Hong Yuan; Xuan-Yi Wang; Yu-Mei Wen
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

10.  Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection.

Authors:  Abhishek Das; Matthew Hoare; Nathan Davies; A Ross Lopes; Claire Dunn; Patrick T F Kennedy; Graeme Alexander; Helene Finney; Alistair Lawson; Fiona J Plunkett; Antonio Bertoletti; Arne N Akbar; Mala K Maini
Journal:  J Exp Med       Date:  2008-08-11       Impact factor: 14.307
View more
  6 in total

1.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 2.  Advances in therapeutics for chronic hepatitis B.

Authors:  Ninghan Yang; Antonio Bertoletti
Journal:  Hepatol Int       Date:  2015-09-12       Impact factor: 6.047

Review 3.  The Role of cccDNA in HBV Maintenance.

Authors:  Lena Allweiss; Maura Dandri
Journal:  Viruses       Date:  2017-06-21       Impact factor: 5.048

4.  Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment.

Authors:  Jiezuan Yang; Dong Yan; Renyong Guo; Jiajia Chen; Yongtao Li; Jun Fan; Xuyan Fu; Xinsheng Yao; Hongyan Diao; Lanjuan Li
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 5.  Immunotherapy for Chronic Hepatitis B Virus Infection.

Authors:  Antonio Bertoletti; Nina Le Bert
Journal:  Gut Liver       Date:  2018-09-15       Impact factor: 4.519

6.  Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis.

Authors:  Liting Tian; Qilin Fu; Fu Huang
Journal:  Exp Ther Med       Date:  2016-08-29       Impact factor: 2.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.